<DOC>
	<DOCNO>NCT01870921</DOCNO>
	<brief_summary>A multicenter , single arm , open label , Phase IV study evaluate safety describe incidence major cardiovascular event ticagrelor Chinese patient acute coronary syndrome</brief_summary>
	<brief_title>Brilinta DaYu Study</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Female male age least 18 year 2.Index event nonST ST segment elevation ACS 3.A patient consider ethnic Chinese 1 . With coagulation disorder 2.Index event acute complication PCI 3.Patient plan urgent coronary artery bypass graft ( CABG ) within 7days enrolment 4.Oral anticoagulation therapy within 30 day prior enrolment stop 5.Increased risk bradycardic event 6 . Concomitant oral intravenous therapy ( see example ) strong CYP3A inhibitor , CYP3A substrates narrow therapeutic index , strong CYP3A inducer 7.Increased risk bradycardic event ( eg , pacemaker know sick sinus syndrome , second degree AV block , third degree AV block previous document syncope suspect due bradycardia unless treat pacemaker ) . 8.Known clinically important thrombocytopenia 9.Known clinically important anaemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>